Cancer researchers find "danger" receptor

23 February 2009

Cancer Research UK, a charity funded by private donations, has published a report that claims to have found the first biological receptor that  alerts the immune system to abnormal cell death, in the journal Nature.

It has been thought that this type of cell death could kick-start an  immune response because an injury could be accompanied by an infection.  In addition, some tumors could trigger this type of reaction, because  they often have clusters of cells undergoing abnormal cell death at  their core as they feed off a limited blood supply. The receptor, called  DNGR-1, is found on dendritic cells, messengers that instruct T cells to  attack foreign invaders.

Caetano Reis e Sousa, lead author of the study, said: "the detection of  'danger' could explain some situations when a tumor triggers an immune  reaction against itself."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight